ONCY - Earnings announcements

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareo

American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first qu

Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assistance, plea

Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assista

Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter 2024. Conference Call & Webcast Date: Tuesday, November 12, 2024Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 5

Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 million provides runway through key milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, Aug. 1, 2024 /PRNewswire/ -- Oncolytics B

Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024. Conference Call & WebcastDate: Thursday, August 1, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In – International: (646) 357-8785RapidConnect: to join the conference call without operator assi

Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival data from BRACELET-1 breast cancer study expected in H2 2024 Cash position of $29.6 million provides runway through critical milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31

Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, April 30, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2024. Conference Call & Webcast Date: Thursday, May 9, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (800) 836-8184Dial In

Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 4, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2023. https://mma.prnewswire.com/media/1762876/4573053/Oncolytics_Biotech_New_Logo.jpg Conference Call & Webcast Date: Thursday, March 7, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Ra

Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, March 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it will host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2023. https://mma.prnewswire.com/media/1762876/4573053/Oncolytics_Biotech_New_Logo.jpg Conference Call & Webcast Date: Thursday, March 7, 2024Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764

Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 4, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2023. Conference Call & WebcastDate: Monday, August 14, 2023Time: 8:30 a.m. ETDial-In – North American Toll-Free: (888) 664-6383Dial-In – International: (416) 764-8650RapidConnect: to join the conference call without operator assistance, please click hereConference ID (if needed): 5411-4798Webcast: please click here A webcast of

Conference call and webcast to take place on Monday, August 14, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 4, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2023. Conference Call & WebcastDate: Monday, August 14, 2023Time: 8:30 a.m. ETDial-In – North American Toll-Free: (888) 664-6383Dial-In – International: (416) 764-8650RapidConnect: to join the conference call without operator assistance, please click hereConference ID (if needed): 5411-4798Webcast: please click here A web

Randomized phase 2 data from BRACELET-1 trial in HR+/HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Guidance on the registration paths for pelareorep in HR+/HER2- metastatic breast and first-line pancreatic cancer expected in H2 2023 $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected cash runway for at least 12 months Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Calif. and CALGARY, AB, May 5, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced recent operational highlights and fina

Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023. Conference Call & WebcastDate: Friday, May 5, 2023Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650RapidConnect: to join the conference call without ope

Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients Phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer on track for a randomized data readout in Q2 2023 that will inform the design of a pivotal trial Registration opportunities in breast and pancreatic cancer are supported by FDA Fast Track designations $32.1 million in cash, cash equivalents and marketable securities as of December 31, 2022 provides projected runway through BRACELET-1's upcoming readout and into 2024 Management hosting conference call and webcast today at 8:30 a.m. ET

Conference call and webcast to take place on Friday, March 3, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 21, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, March 3, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2022. Conference Call & Webcast Date: Friday, March 3, 2023 Time: 8:30 a.m. ET Dial In – North American Toll-Free: (888) 664-6383 Dial In – International: (416) 764-8650 RapidConnect: to join the co

Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials Pipeline now provides multiple registration opportunities in breast and pancreatic cancer $32.4 million in cash and cash equivalents as of September 30, 2022 provides projected runway through key milestones to the end of 2023 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced recent operational highlights and financial results for the third quarter ended Se

70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4 Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma Oncolytics plans to present pancreatic cancer data to regulators to determine the most expeditious path to approval Company management to discuss these results and ongoing efforts to advance pelareorep into registration studies in breast and pancreatic cancer during Q3 earnings call today at 8:30 a.m. ET Updated data from GOBLET's pancreatic cancer cohort to be presented in a poster at the SITC meeting and discussed during a

Conference call and webcast to take place on Monday, November 7, 2022, at 8:30 a.m. ET SAN DIEGO, Calif. and CALGARY, AB, Oct. 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Monday, November 7, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2022.   Conference Call & Webcast Date: Monday, November 7, 2022Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Conference ID (if needed): 4240-6541Webcast: please click here A webcast of the call will also be available on the Investor Relations page of

Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients Clinical biomarker data show pelareorep remodeling tumor microenvironments to improve prognosis and decrease the risk of recurrence in HR+/HER2- breast cancer patients $33.7 million in cash and cash equivalents provides projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer Management hosting conference call and web

Conference call and webcast to take place on Thursday, August 11, 2022, at 8:30 a.m. ET SAN DIEGO, CA and CALGARY, AB, July 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2022. Conference Call & Webcast Date: Thursday, August 11, 2022Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 220-8474Dial In – International: (647) 484-0475Conference ID (if needed):

Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's induced improvement in the prognosis of HR+/HER2- breast cancer patients by decreasing their risk of recurrence Preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with CAR T cell therapy in solid tumors published in Science Translational Medicine $39.5 million in cash and cash equivalents expected to provide runway through key catalysts and into 2023 Management hosting conference call and webcast today at 5:00 p.m. ET SAN DIEGO, Calif and CALGARY, AB, M

Conference call and webcast to take place on Thursday, May 5, 2022, at 5:00 p.m. ET SAN DIEGO and CALGARY, AB, April 28, 2022 /PRNewswire/ --Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Thursday, May 5, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the first quarter of 2022. Conference Call & Webcast Date: Thursday, May 5, 2022Time: 5:00 p.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Conference ID (if needed): 6952-6976Webcast:

SAN DIEGO, Calif.  and CALGARY, AB, Feb. 22, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021. Conference Call & Webcast Date: Thursday, March 3, 2022Time: 5:00 p.m. Eastern Standard TimeDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Conference ID (if needed): 4650-7590Webcast: please click here A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will b

Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker Advanced collaboration with Roche and AIO by initiating dosing in phase 1/2 GOBLET trial in gastrointestinal cancers Strong financial position with approximately $48 million and cash runway into 2023 Management hosting conference call and webcast today at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, Nov. 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced its financial results and development highlights for the quarter ended September 30, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted. "Over the past f

SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021. Conference Call & Webcast Date: Friday, November 5, 2021Time: 8:00 a.m. Eastern Daylight TimeDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Conference ID (if needed): 7285-9440Webcast: please click here A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for thre

- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer - Phase 2 BRACELET-1 (breast cancer) trial remains on track for full enrollment in Q4 2021 - Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareorep's broad applicability to a number of different tumor types - Strong financial foundation with approximately $50.8 million in cash on hand and cash runway into 2023 - Management hosting conference call and webcast today at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswi

Conference call and webcast to take place on Friday, August 6, 2021, at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, July 22, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, August 6, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the second quarter 2021. Conference Call & Webcast Date: Friday, August 6, 2021Time: 8:00 a.m. Eastern Daylight TimeDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650Conference ID (if needed): 5114-8191Webcast: please click here A webcast of the call will also be available on the Investor Relations page

- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareorep's synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021 - Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022 SAN DIEGO and CALGARY, AB, May 7, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced